Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - Pipeline Insight, 2024

This “Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Understanding

Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Overview

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a disease caused by the destabilization of a transport protein called transthyretin which leads to the abnormal deposition of amyloid protein in the heart. The disease is characterized by the depositions of amyloid protein fibrils in the left ventricle walls, which is the main pumping chamber of the heart. ATTR-CM has two subtypes- wild type and hereditary type. The wild type ATTR-CM happens without mutation and is thought to occur due to aging and majorly affects men above the age of 60. The Hereditary ATTR-CM is said to occur due to the mutation in the transthyretin gene and may be observed in individuals in the 50-60 age group.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) pipeline landscape is provided which includes the disease overview and Transthyretin Amyloid Cardiomyopathy (ATTR-CM) treatment guidelines. The assessment part of the report embraces, in depth Transthyretin Amyloid Cardiomyopathy (ATTR-CM) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Transthyretin Amyloid Cardiomyopathy (ATTR-CM) R&D. The therapies under development are focused on novel approaches to treat/improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM).

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Emerging Drugs Chapters

This segment of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Emerging Drugs

Acoramidis (AG 10): Eidos Therapeutics Eidos therapeutics’ drug candidate AG 10 is in the phase III stage of drug development currently. The molecule was designed to stabilize TTR by copying the T119M- TTR variant’s structure.

NI006: Neura Immune Therapeutics NI006, a NeuraImmune Therapeutics’ drug candidate is a human antibody that specifically targets only the disease-associated conformation of the amyloid protein. The drug molecule is capable of targeting boththe ATTR linked with hereditary ATTR-CM as well as the wild type. Currently, it is in the Phase I of the drugdevelopment.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Therapeutic Assessment

This segment of the report provides insights about the different Transthyretin Amyloid Cardiomyopathy (ATTR-CM) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

There are approx. 3+ key companies which are developing the therapies for Transthyretin Amyloid Cardiomyopathy (ATTR-CM). The companies which have their Transthyretin Amyloid Cardiomyopathy (ATTR-CM) drug candidates in the mid to advanced stage, i.e. phase III include, Neura Immune Therapeutics andothers.

Phases

This report covers around 3+ products under different phases of clinical development like
? Late-stage products(Phase III)
? Mid-stage products (Phase II and Phase I/II)
? Early-stage products (Phase I/II and Phase I) along with the details of
? Pre-clinical and Discovery stage candidates
? Discontinued & Inactive candidates

Route of Administration

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
? Subcutaneous
? Intravenous
? Oral
? Intramuscular

• Molecule Type

Products have been categorized under various Molecule types such as

? Small molecules
? Natural metabolites
? Monoclonal antibodies

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Transthyretin Amyloid Cardiomyopathy (ATTR-CM) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Transthyretin Amyloid Cardiomyopathy (ATTR-CM) drugs.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Report Insights

• Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Transthyretin Amyloid Cardiomyopathy (ATTR-CM) drugs?
• How many Transthyretin Amyloid Cardiomyopathy (ATTR-CM) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Eidos Therapeutics
• Neura ImmuneTherapeutics

Key Products

• Acoramidis
• NI006

This product will be delivered within 2 business days.